Otitis Media: Why Is it so Difficult to Treat or Prevent?  by Navarro-Locsin, G.
e iona
3
O
G
Q
O
e
o
m
c
(
O
e
a
t
m
m
w
a
m
o
a
n
i
l
i
c
o
m
a
p
A
P
1
g
a
i
e
r
p
p
r
R
d
3
P
R
P
S
t
i
m
H
r
n
e
9
v
s
a
a
i
b
g
a
o
q
o
s
e
v
s
c
b
t
t
j
p
R
d
I4 13th Internat
.004
titis Media: Why Is it so Difﬁcult to Treat or Prevent?
. Navarro-Locsin
Pediatric Otorhinolaryngologist, St. Luke’s Medical Center,
uezon City, Philippines
titis media (OM), one of the most common childhood dis-
ases, is a polymicrobial disease encompassing a spectrum
f ear conditions that can lead to complications such as
astoiditis, invasive disease and hearing loss. Streptococ-
us pneumoniae and non-typable Haemophilus inﬂuenzae
NTHi) account for up to 80% of cases of bacterial acute
M (AOM) worldwide. There is a direct relationship between
arly nasopharyngeal colonisation by S. pneumonia and NTHi
nd early ﬁrst episodes of AOM, and failure to eradicate
hese pathogens (particularly NTHi) completely from the
iddle ear is associated with treatment failure.1 Further-
ore, over 50% of H. inﬂuenzae isolates from patients
ith recurrent and refractory OM produce b-lactamase and
re intrinsically resistant to ampicillin and amoxicillin, the
ainstays of treatment.
Accurate diagnosis of OM aetiology in young children is
ften difﬁcult, so AOM is usually treated empirically with
ntibiotics without identifying the causative pathogen. Such
on-targeted therapy contributes to treatment failure and
ncreasing antibiotic resistance. Despite treatment guide-
ines that call for watchful waiting, AOM is the leading
ndication for antibiotic prescription in many developed
ountries.2
Preventing the ﬁrst episode of AOM is probably the
ptimal approach to reducing the burden of OM. The pneu-
ococcal conjugate vaccine (PCV)-7 has had modest success
gainst all-cause OM,3 possibly because it targets only S.
neumoniae. Post-PCV-7, an increase in the proportion of
OM cases attributable to NTHi has been observed.4,5 The
neumococcal Otitis Efﬁcacy Trial (POET) showed that the
1-valent pneumococcal H. inﬂuenzae protein D - conju-
ate vaccine candidate reduced 35.3% of NTHi-attributable
nd 57.6% of S. pneumoniae-attributable AOM cases, result-
ng in a clinically relevant 33.6% prevention of overall AOM
pisodes.6 Taking into account the dynamics of nasopha-
yngeal colonisation by S. pneumoniae and NTHi, a dual
athogen vaccine like the protein D conjugate vaccine, cou-
led with judicious antibiotic treatment, could substantially
educe the burden of AOM.
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reventing Pneumonia: Lessons and Future Implications
. Dagan
Beer Sheva University, Beer Sheva, Israel
neumonia is the leading killer of children worldwide.1
treptococcus pneumoniae and Haemophilus inﬂuenzae
ype b (Hib) are the leading causes of bacterial pneumonia
n young children, with S. pneumoniae being the most com-
on cause. The role of other bacteria such as non-typable
. inﬂuenzae (NTHi) in childhood pneumonia is not clear.
Hib conjugate vaccines almost eliminated Hib disease in
egions where they were introduced into the national immu-
isation programme, and they demonstrated protective
fﬁcacy against Hib bactaeremic pneumonia [69% (3—90%;
5% CI)].2 Seven- and nine-valent pneumococcal conjugate
accines (PCVs) reduced the incidence of (and hospitali-
ation caused by) vaccine-serotype pneumonia in children
ged less than 2 years.3 Additionally, the PCVs reduced
ll-cause pneumonia in vaccinees and their contacts (herd
mmunity).4 The PCVs also reduced rates of disease caused
y antibiotic-resistant S. pneumoniae.5
The characteristics of Hib and pneumococcal conju-
ate vaccines thought to be associated with protection
gainst pneumonia are multi-factorial. Vaccine induction
f functional protective immunity is critical for ade-
uate protection against pneumonia, as is the induction
f immunological memory. For a new conjugate vaccine, a
imilar immunogenicity proﬁle to existing vaccines that are
ffective against pneumonia may suggest similar efﬁcacy. A
accine class effect could therefore be envisaged providing
everal criteria are met, such as adequate opsonophago-
ytic titres and anti-pneumococcal IgG concentrations, and
oostability. Under a vaccine class effect, notwithstanding
he caveats pertaining to it, a new candidate PCV such as
he Pneumococcal Haemophilus inﬂuenzae Protein D - Con-
ugate Vaccine (PHiD-CV) might also be expected to offer
rotection against pneumonia.
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lose Encounters of the ETEC-type
. Cravioto ∗, F. QadrilICDDR, B, Dhaka, Bangladesh
nterotoxigenic Escherichia coli (ETEC) is a multivalent
athogenic organism that has been sub-classiﬁed into differ-
nt phenotypic groups based on the type of exoproteins it
